Seattle | June 1, 2017 : The Infectious Disease Research Institute (IDRI) announced today that Corey Casper, MD, MPH, has joined IDRI’s executive team as its Chief Medical Officer. Casper comes to IDRI from the Fred Hutchinson Cancer Research Center and the University of Washington, and brings extensive experience leading multi-phased international clinical trials from conception to publication to U.S. Food and Drug Administration (FDA) licensure.
In his role as IDRI’s Chief Medical Officer, Casper will develop and lead all clinical trial programs for IDRI from preclinical to Phase III, including oversight and management of data functions.
“As more IDRI products move into and through the clinical trial phase, we’re pleased to have Corey lead this very important translational part of our mission,” said Steve Reed, PhD, IDRI’s President, CEO & Founder. “Corey also has extensive expertise collaborating with leaders in government and academia, as well as the public and nonprofit sectors. This experience is very valuable to IDRI as product partnerships have become an increasingly important part of our business model.”
Casper has more than 20 years of experience in designing, growing and sustaining internationally-recognized programs in infection-related cancers, HIV, infection control and global oncology. Casper most recently served as a Full Member in the Vaccine and Infectious Disease, Clinical Research and Public Health Sciences Divisions at the Fred Hutchison Cancer Research Center where he founded and directed the one of the nation’s first and most effective outpatient infection control programs; he also founded and directed the first Global Oncology program at a designated comprehensive cancer center. At the University of Washington, Casper was appointed as a Professor of Medicine, Epidemiology and Global Health, and served as the Co-Director of the Center for AIDS Research. Casper has held several clinical positions, including serving as an attending physician for the Seattle Cancer Care Alliance’s Infectious Disease Consult Service.
“IDRI is unique in that the organization has the scientific strength to develop new strategies against infectious pathogens in their laboratories, manufacture products within their own facilities, and partner with teams around the world to test and apply therapies for some of the most important infectious pathogens afflicting the world today,” said Casper. “I am tremendously excited to join IDRI and work with the outstanding scientific and leadership teams to bring basic discoveries through late-stage clinical testing, with the ultimate goal to reduce the burden of infectious diseases in both low- and high-resource settings.”
With more than 80 peer-reviewed publications, Casper’s research efforts focus on the transmission, acquisition, natural history, pathophysiology and treatment of infection-associated cancers with a special focus on the human herpesviruses (Epstein Barr Virus and Human Herpesvirus-8).
In 2004, Casper initiated a collaboration with physician-scientists at the Uganda Cancer Institute (UCI) and the Kampala Cancer Registry, resulting in the formation of the Uganda Program in Cancer and Infectious Diseases (UPCID), now known as the UCI/Hutchinson Center Cancer Alliance. As Director of this alliance, he established a translational clinical research site in Kampala, which has conducted more than two dozen clinical research studies.
“Corey has played a key role in establishing this partnership, which supports the development of biomedical infrastructure in Africa,” said Reed. “This commitment to local capacity building matches well with IDRI’s, as we continue to expand our efforts in this area.” IDRI has established a company in South Africa, called Afrigen Biologics, which is using IDRI technology to innovate areas of vaccine development for infectious diseases.
In addition to his clinical and research work, Casper is a committed educator who has successfully mentored many graduate and post-graduate trainees in infectious diseases and global health. Casper obtained an undergraduate degree in Biology from Wesleyan University, his MD from Cornell University Medical College and a Master of Public Health degree from the University of Washington.
STINCHCOMB NAMED IDRI CSO
In addition to naming Casper as CMO, IDRI has promoted Dan Stinchcomb, PhD, who joined IDRI in April 2016 as Sr. Vice President for Vaccine Development and Viral Disease Programs, to Chief Scientific Officer. He will lead scientific operations and execute the scientific strategy for the organization. With extensive knowledge in the field of viral diseases, Stinchcomb has more than 25 years of biotechnology experience leading research and product development efforts for therapeutics, vaccines and diagnostics to improve human and animal health. biotechnology experience leading research and product development efforts for therapeutics, vaccines and diagnostics to improve human and animal health.
As a nonprofit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world.